These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 28046101)
1. Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary. Scribner E; Fathallah-Shaykh HM PLoS One; 2017; 12(1):e0169434. PubMed ID: 28046101 [TBL] [Abstract][Full Text] [Related]
2. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth. Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139 [TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171 [TBL] [Abstract][Full Text] [Related]
5. Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions. Scribner E; Saut O; Province P; Bag A; Colin T; Fathallah-Shaykh HM PLoS One; 2014; 9(12):e115018. PubMed ID: 25506702 [TBL] [Abstract][Full Text] [Related]
6. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. Xu H; Rahimpour S; Nesvick CL; Zhang X; Ma J; Zhang M; Zhang G; Wang L; Yang C; Hong CS; Germanwala AV; Elder JB; Ray-Chaudhury A; Yao Y; Gilbert MR; Lonser RR; Heiss JD; Brady RO; Mao Y; Qin J; Zhuang Z Oncotarget; 2015 May; 6(14):11882-93. PubMed ID: 25957416 [TBL] [Abstract][Full Text] [Related]
8. First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report. O'Connell D; Shen V; Loudon W; Bota DA CNS Oncol; 2017 Jan; 6(1):11-18. PubMed ID: 27918194 [TBL] [Abstract][Full Text] [Related]
9. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. Bambury RM; Morris PG Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143 [TBL] [Abstract][Full Text] [Related]
10. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Chinot OL Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106 [TBL] [Abstract][Full Text] [Related]
12. Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Oliver L; Olivier C; Marhuenda FB; Campone M; Vallette FM Curr Mol Pharmacol; 2009 Nov; 2(3):263-84. PubMed ID: 20021464 [TBL] [Abstract][Full Text] [Related]
13. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Verhoeff JJ; Stalpers LJ; Claes A; Hovinga KE; Musters GD; Peter Vandertop W; Richel DJ; Leenders WP; van Furth WR Eur J Cancer; 2009 Nov; 45(17):3074-80. PubMed ID: 19734041 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329 [TBL] [Abstract][Full Text] [Related]
15. Controlling tumor invasion: bevacizumab and BMP4 for glioblastoma. Rahman M; Azari H; Deleyrolle L; Millette S; Zeng H; Reynolds BA Future Oncol; 2013 Sep; 9(9):1389-96. PubMed ID: 23980685 [TBL] [Abstract][Full Text] [Related]
16. Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans. Stadlbauer A; Kinfe TM; Eyüpoglu I; Zimmermann M; Kitzwögerer M; Podar K; Buchfelder M; Heinz G; Oberndorfer S; Marhold F Clin Cancer Res; 2021 Mar; 27(6):1641-1649. PubMed ID: 33293375 [TBL] [Abstract][Full Text] [Related]
17. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Kesari S Semin Oncol; 2011 Dec; 38 Suppl 4():S2-10. PubMed ID: 22078644 [TBL] [Abstract][Full Text] [Related]
18. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121 [TBL] [Abstract][Full Text] [Related]
19. A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden. Sandström M; Laudius M; Lindqvist T; Asklund T; Johansson M Anticancer Res; 2017 Apr; 37(4):1869-1874. PubMed ID: 28373454 [TBL] [Abstract][Full Text] [Related]
20. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Narita Y Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]